Sandostatin — CareFirst (Caremark)
Cancer-related diarrhea
Initial criteria
- Treatment of cancer-related diarrhea when the member has grade 3 or greater diarrhea according to NCI CTCAE
Reauthorization criteria
- Member is experiencing clinical benefit as evidenced by improvement or stabilization in clinical signs and symptoms since initiation of therapy
Approval duration
12 months